AstraZeneca has been cleared to include cardiovascular and kidney outcomes data on the label of its type 2 diabetes therapy Forxiga in the EU which could help it challenge rival drugs in the SGLT2 ...
Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction, after getting a green light from the EMA's human medicine committee.
Abstract: Existing Zero-Shot Learning (ZSL) approaches for sensor-based Human Activity Recognition (HAR) often rely on external semantic information—such as attribute annotations or textual ...
An Advanced Machine Learning Framework for Multi-Label Classification of Heart Disease Complications
Abstract: Heart disease continues to be the foremost cause of mortality across both developed and developing nations, posing a critical public health challenge. This life-threatening condition often ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback